Proprietary fermentation-enabled process offers numerous performance, sustainability and economic advantages over traditional plant extraction techniques
BERKELEY, Calif., Oct. 26, 2020 — Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced the launch of Lygos CBx, a Lygos company and new website focused on delivering a wide range of high-quality, pure and sustainable non-plant-based cannabinoids. Lygos CBx is a result of the combination of Librede, the recently acquired NIH-funded biosynthetic company, and the integration of key Lygos technology advances. Recent validation projects have demonstrated the company’s ability to produce a variety of cannabinoids and cannabinoid-based products in an environmentally safe, sustainable and cost-effective manner for commercial applications.
Lygos CBx utilizes its novel production pathway to provide a high-performance alternative to agricultural-based cannabinoid production. The company currently offers a full menu of common, rare or novel cannabinoids, along with leading bulk supply, formulation, custom synthesis, and efficacy services to help meet the particular needs of its current and future customers in the consumer products and pharmaceuticals industries. Lygos CBx is actively engaging new partnerships and expects to make additional co-development and commercialization announcements before the end of the year.
“The launch of Lygos CBx is a reflection of all the hard work required to develop a novel production platform that can introduce disruptive consumer products and brands in a rapid and repeatable manner,” said Eric Steen, PhD, CEO of Lygos. “Today, we are currently delivering high-quality, ultra-pure and sustainable cannabinoids and partnering with industry leaders to help meet the growing demand for these next-generation products.”
Lygos CBx’ bio-based production platform features important quality control measures that ensure pure, consistent and replicable ingredients over time. The technology produces precise, specific and isolated cannabinoids, and avoids issues of separation and purification compared to plant-based production. The modular platform is able to produce a variety of both acidic and decarboxylated forms. In addition to the production of natural molecules, the same modular platform can also create cannabinoid-like derivatives for pharmaceutical applications that target the human endocannabinoid system.
About Lygos CBx
Lygos CBx is a Lygos company focused on low-cost, industrial-scale production of a wide range of high-quality, pure and sustainable cannabinoids that are not easily accessible through traditional agricultural means. Lygos CBx is a direct result of the recent NIH-funded Librede acquisition and integration of additional Lygos technology advances. The cannabinoids are designed to enhance numerous consumer products, as well as health & wellness and pharmaceutical applications. For more information, visit cbx.lygos.com.
Lygos has created a full-stack biological engineering platform focused on organic acid specialty ingredients, health & wellness ingredients, including cannabinoids and bio-monomers. Lygos’ sustainable, bio-based chemicals replace expensive, environmentally degrading alternatives from traditional industrial suppliers, enabling customers to create better, safer products with value-added performance. For more information, visit www.lygos.com and follow us @LygosBiotech.
Lygos, Lygos CBx, Librede, and the Lygos and Lygos CBx logos are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.